Owkin

Name

Owkin

Legal name

Owkin Inc.

Website

https://owkin.com

Company type

Private

Founded year

2016

Operating status

Operating

Short description

Owkin is a Paris-headquartered AI-native biotech building the K Pro agentic AI scientist platform for biopharma R&D, licensed to top pharmaceutical companies on multi-year enterprise contracts.

Ownership category

akta.pro rank

Product category

Biopharma AI Platform

NAICS

Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Prepackaged Software (7372), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM)

Keywords

• AI drug discovery
• Federated learning healthcare
• Digital pathology diagnostics
• Clinical trial optimization
• Multimodal patient data

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. K Pro Platform Licensing: Owkin licenses its K Pro AI scientist platform to pharmaceutical companies through multi-year agreements. The platform is deployed within customers' own systems, with Owkin overseeing end-to-end construction of agentic AI tools. Pricing is based on multi-year licensing arrangements.
2. AI Development Partnerships: Co-development agreements with pharmaceutical companies for bespoke AI agents and solutions. These strategic partnerships involve collaborative development of AI tools tailored to specific drug discovery and development workflows.
3. Diagnostic Products: AI-powered precision diagnostics including MSIntuit CRC (CE-IVD marked), RlapsRisk BC, and BRCAura for cancer diagnostics. Products are deployed through distribution partnerships including Roche's navify Digital Pathology platform.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Owkin develops and licenses an agentic AI platform (K Pro) that supports biopharmaceutical R&D by analyzing multimodal patient data from a federated network of more than 800 hospitals. The platform combines foundation models, AI agents, and federated learning to inform drug target identification, clinical trial design, biomarker discovery, and patient stratification decisions for pharmaceutical and clinical customers.

Differentiator

Problem solved

Functional benefit

Brands

• Waiv: Diagnostic testing spinout formerly known as Owkin Dx, focused on biomedical analysis services and now operating as an independent company with Owkin holding a minority stake.

Products and services

• K Pro An autonomous AI scientist platform that informs decision-making and generates insights across biopharmaceutical R&D, fusing multimodal patient datasets with biological AI systems to accelerate decision-making from early-stage discovery to clinical development. Delivered as a multi-year license to pharmaceutical companies and deployed within customers' own systems.
• K Navigator An agentic AI software platform for academic biomedical researchers that analyzes multiomic patient data and navigates biomedical literature across 26.5 million articles and 19 major databases.
• Pathology Explorer A specialized AI agent for pan-cancer nuclei detection, segmentation and classification in H&E-stained pathology images. Delivers 23.7% better classification accuracy while using five times fewer parameters, and is available through Anthropic's Claude for Healthcare and Life Sciences platform.

Quantifiable outcome

• 70% reduction in drug target identification time
• +5 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature11 records

Partnerships

20 partnerships are on record, tiered core, strategic, major and minor.

• Cleveland Clinic Abu DhabicoreStrategic or Co-development Partner · 17 June 2026Collaboration to launch 'Aila', world's first clinical AI scientist designed to support real-time clinical decision-making and accelerate medical research using real patient data. Initial deployment focuses on prostate cancer, integrating EHR, pathology reports, and medical imaging.
• SanoficoreStrategic or Co-development Partner · 5 June 2026Five-year K Pro licensing agreement to co-develop next-generation AI-driven biopharma agents. Builds on €90m collaboration since 2021 focused on oncology target identification expanded to immunology. Owkin oversees end-to-end construction of agentic AI tools deployed through K Pro within Sanofi's systems.
• AstraZenecacoreStrategic or Co-development Partner · 13 May 2026Three-year K Pro licensing agreement for biopharma AI agents integrated into AstraZeneca's IT infrastructure. Agents provide competitive intelligence capabilities for analyzing pharmaceutical targets, assets, trials, and competitive landscape. Prior collaboration produced BRCAura breast cancer AI solution.
• WaivcoreStrategic or Co-development Partner · 12 March 2026Spin-out from Owkin's diagnostic division with $33M financing. Waiv develops AI-powered precision diagnostics including RlapsRisk BC, MSIntuit Suite, and BRCAura. Owkin retains minority stake and strategic ties as patient validation ecosystem partner.
• 4baseCarestrategicStrategic or Co-development Partner · 18 February 2026Precision oncology research collaboration announced at Global AI Impact Summit 2026, India. Partnership aims to advance inclusive precision oncology research using diverse datasets.
• OmicsBankstrategicStrategic or Co-development Partner · 18 February 2026Partnership announced at Global AI Impact Summit 2026, India to develop more inclusive biological AI and advance drug discovery using India's healthcare data infrastructure.
• AnthropiccoreTechnology or Integration · 12 January 2026Pathology Explorer AI agent integrated through Anthropic's Claude for Healthcare and Life Sciences platform via Model Context Protocol (MCP). Enables healthcare professionals to utilize advanced pathology analysis capabilities within Claude's platform.
• NVIDIAcoreTechnology or Integration · 12 January 2026Ongoing collaboration benchmarking state-of-the-art NVIDIA models on rigorous biological reasoning tasks to fuel K Pro development. Partnership to advance foundation model capabilities for digital pathology and multiomics analysis.
• Université Paris-SaclaymajorStrategic or Co-development Partner · 20 November 2025MoU to integrate Owkin's K Pro Free AI co-pilot into university biomedical research and education. Partnership aims to enhance research efficiency and innovation in healthcare.
• Gustave RoussycoreStrategic or Co-development Partner · 18 November 2025Partnership at Franco-German Digital Sovereignty Summit to build Europe's first pan-European agentic infrastructure for biology. Combines agentic AI systems with biomedical data structuring to accelerate drug development across European institutions.
• Charité Comprehensive Cancer Center (Berlin)coreStrategic or Co-development Partner · 18 November 2025Partnership with Gustave Roussy to build Europe's first pan-European agentic infrastructure for biology at Franco-German Summit on Digital Sovereignty. Initiative positions Europe to lead in AI-native biology.
• EpkincoreOthers · 18 November 2025Affiliate company sponsoring OKN4395 clinical trial. Part of Owkin group's strategy to build specialized independent businesses.
• IDISBa (Fundación Instituto de Investigación Sanitaria Islas Baleares)majorStrategic or Co-development Partner · 5 November 2025Partnership to use AI to improve cardiovascular disease outcomes, beginning with hypertrophic cardiomyopathy research. Includes structuring AI-ready database and developing data management strategies.
• MicregenminorStrategic or Co-development Partner · 5 November 2025Micregen used Owkin K platform to prepare investment round materials and validate research for MRG1061 therapeutic candidate targeting pediatric rare diseases.
• Medical University of Vienna / University Hospital ViennamajorStrategic or Co-development Partner · 22 August 2025Strategic collaboration to deploy Owkin K AI copilot within Vienna's oncology ecosystem. Initial focus on urologic cancers beginning with advanced bladder cancer, enabling researchers to query multimodal patient data.
• NeoGenomicsmajorStrategic or Co-development Partner · 29 July 2025Partnership with France Tissue Bank to develop first foundation model exclusively trained on immunohistochemistry (IHC) images for AI-driven ADC diagnostics. Leverages NeoGenomics' dataset of 2.5M+ digitized pathology images.
• Hôpital FochmajorStrategic or Co-development Partner · 1 July 2025Framework agreement to test and validate AI-identified cancer biomarkers on human tumor samples. Builds on prior bladder cancer project where Foch provided samples for organoid validation of AI discoveries.
• Graeme Bell (CFO)coreOthers · 5 May 2025Appointment of Graeme Bell as Chief Financial Officer to strengthen financial leadership.
• Absci CorporationmajorStrategic or Co-development Partner · 10 January 2025Strategic partnership combining Absci's generative AI de novo antibody design with Owkin's predictive AI models optimized through biomedical datasets and patient-derived organoids. Collaboration targets immuno-oncology and other indications including immunology and inflammation.
• MSD (Merck & Co)majorStrategic or Co-development Partner · 19 August 2024Pilot program to evaluate MSIntuit CRC digital pathology diagnostic tool on patient identification for colorectal cancer in European hospitals. Collaboration to assess workflow efficiency, diagnosis speed, and resource utilization.

Scale indicators10 records

Recent moves8 records

Expansion highlights8 records

Emerging players

• BPGbio: AI-driven biopharma company combining patient-derived data with computational biology for drug discovery. Comparable as a smaller competitor working at the intersection of patient data, AI, and pharma partnerships.
• XtalPi: AI and quantum physics-driven drug discovery company serving pharma partners. Comparable as an AI-driven pharma platform with overlapping enterprise sales motion, though with more emphasis on computational chemistry than multimodal patient data.

Direct peers

• Schrödinger: Computational chemistry and AI drug discovery platform serving pharma customers with predictive modeling and collaboration agreements. Directly comparable for AI-driven molecular design and pharma enterprise sales model.
• PathAI: AI-powered digital pathology company serving pharma and diagnostics. Directly comparable for Owkin's Pathology Explorer and federated pathology model work, with overlapping biotech customers and pathology AI products.
• Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology, partnering with major pharma (Bristol Myers Squibb, Eli Lilly). Directly comparable as a platform applying AI to pharma R&D with multi-year enterprise licenses and multimodal patient data integration.
• Exscientia: AI-driven precision medicine and drug discovery company with pharma partnerships. Directly comparable as a competing AI R&D platform with similar enterprise licensing motions and patient-derived data integration.
• Isomorphic Labs: Alphabet-backed AI drug discovery company spun out of DeepMind, partnering with Novartis and Eli Lilly on multi-year deals. Directly comparable as a foundation-model-driven drug discovery platform competing for the same top-10 pharma enterprise relationships.
• Recursion Pharmaceuticals: Publicly listed AI-for-drug-discovery company using foundation models and high-throughput experimental data to discover therapeutics. Directly comparable as a competing AI R&D platform selling multi-program partnerships to large pharma customers.
• Iambic Therapeutics: AI-driven drug discovery company combining foundation models with physics-based simulation for therapeutic design. Comparable as a newer entrant in the AI-for-pharma platform category targeting large-pharma partnerships.

Broad incumbents

• Tempus AI: Large-scale healthcare data and AI platform aggregating multimodal patient data for clinical and research use. Comparable as a broader player operating in adjacent territory—patient data licensing and AI for pharma—though with a wider scope across oncology and clinical care.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/OWKINscience
• GitHubgithub.com/owkin
• YouTubeyoutube.com/@OwkinScience
• LinkedInlinkedin.com/company/owkin
• Instagraminstagram.com/owkinai

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Owkin